Medios AG Reports Robust Earnings Growth in Early 2025

Medios AG has announced strong financial performance for the first nine months of 2025. Revenue climbed by 9.2% to €1,530 million, with a noteworthy 26.1% rise in EBITDA pre1 to €70.4 million. The cash flow from operations nearly doubled, reaching €52.7 million, while earnings per share improved to €0.79. The company's strategic growth is evident across all segments, with International Business posting significant gains.

The Pharmaceutical Supply segment reported a 4.1% revenue increase to €1,239.5 million, enhancing EBITDA pre1 by 4.7%. In Patient-Specific Therapies, revenue rose by 2.7%, with EBITDA pre1 up by 8.4%. The International Business achieved a dramatic revenue surge to €124.2 million, contributing significantly to EBITDA pre1.

Looking ahead, Medios anticipates a 6% revenue increase for the full year, targeting around €2 billion, and expects a further EBITDA pre1 margin rise to 4.8% with new CEO Thomas Meier set to lead the company from February 2026.